Atara Biotherapeutics, Inc. Uncategorized Contracts & Agreements

Amendment No. 1 to the Commercialization Agreement dated September 28, 2022, by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament (Filed With SEC on November 8, 2022)

Commercialization Agreement by and between Atara Biotherapeutics, Inc. and Pierre Fabre Medicament, dated October 2, 2021 (Filed With SEC on February 28, 2022)

Amended and Restated 2018 Inducement Plan (Filed With SEC on November 9, 2020)

Description of Securities (Filed With SEC on February 27, 2020)

Atara Biotherapeutics, Inc. 2018 Inducement Plan (the Inducement Plan) (Filed With SEC on May 8, 2018)

Forms of Inducement Grant Notice and Inducement Grant Agreement (Filed With SEC on August 7, 2017)

4360 Park Terrace Drive WESTLAKE VILLAGE, CALIFORNIA 91361 (Filed With SEC on November 6, 2015)

AMENDMENT NUMBER ONE TO THE EXCLUSIVE OPTION AGREEMENT (Filed With SEC on August 7, 2015)

REVISED (Filed With SEC on July 7, 2015)

EXCLUSIVE OPTION AGREEMENT for MSKs technology EBV/CMV and WT1 specific T-cells (Filed With SEC on May 11, 2015)

SUBLEASEAGREEMENT (Filed With SEC on September 26, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 1 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 2 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

AMENDMENT NO. 3 TO THE EXCLUSIVE LICENSEAGREEMENT (Filed With SEC on June 20, 2014)

OFFICELEASE BASIC LEASEINFORMATION (Filed With SEC on June 20, 2014)